Our infection prevention
solutions reduce the risk of
infections, increase patient
safety and reduce the use of
antibiotics.

A strong year for Bactiguard – investments in organization to capture future growth

Bactiguard Holding AB (publ) published the year-end report for 2022 on Thursday February 9, 2023.

In connection with this, an audiocast for investors, analysts and media was held at 10:00 CET on February 9, 2023. CEO Anders Göransson and CFO Carin Jakobson presented the interim report and answered questions.

Presentation

A strong year for Bactiguard – investments in organization to capture future growth

Prevent the risk of infection

Bactiguard’s BIP Foley catheters decrease the risk of catheter associated urinary tract infection by 69%.

Each year 1 of 10 patients are affected by healthcare associated infections, HAI, globally. The most common HAI is urinary tract infection and a large majority is caused by indwelling urinary catheters.

Prevent the risk of infection

First-in-man clinical study with Bactiguard coated trauma implants published

Bactiguard receives first MDR product approval

Bactiguard receives first MDR product approval

Bactiguard launches Wound Care line in the UK and Ireland

Bactiguard launches Wound Care line in the UK and Ireland

Bactiguard and Zimmer Biomet expand global license partnership

Bactiguard and Zimmer Biomet expand global license partnership